Search - tctmd.com

Displaying 21 - 40 of 100

Sort: Relevancy | Date

Presentation TCT 2017

Debate: How should SFA Disease be Treated? In most cases DCB (± BMS)

Presenter: D. Christopher Metzger

October 30, 2017

Presentation TCT 2017

Emerging Thromboresistant BMS 1: Cobra PzF Stents

Presenter: Julinda Mehilli, Giulio G. Stefanini, Donald Cutlip

October 30, 2017

Presentation TCT 2017

Should BMS Stay On the Shelf? Clinical and Global Perspectives on the Role Of BMS in 2017

Presenter: Julinda Mehilli, Giulio G. Stefanini, Raffaele Piccolo

October 30, 2017

Presentation TCT 2017

The Alphabet of Peripheral Vascular Devices: BMS, DES, PTFE, BVS, and Future Scaffolds

Presenter: Michael Guiry, Julie Logan

October 30, 2017

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Shelley Wood

November 07, 2016

News Industry News TCT 2016

Imaging Study Shows Rate of Strut Coverage and Low Rates of Neouatherosclerosis with Thin Strut Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

November 02, 2016

Presentation TCT 2016

The Alphabet Soup of SFA Scaffolds and Their Outcomes: BMS, VMI, DES, PTFE

Presenter: Tony Das, Koen Deloose, Ehrin J. Armstrong

October 31, 2016

News Conference News TCT 2016

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Todd Neale

October 31, 2016

Presentation TCT 2016

New Insights Into the Mechanisms and Patterns of in-stent Restenosis in BMS and DES Evaluated By IVUS and OCT (With Case Examples)

Presenter: Fernando Alfonso, Stephan Windecker, Akiko Maehara

October 30, 2016

Presentation TCT 2016

Great Debate 2: Implications from NORSTENT: BMS Are Yesterday's History!

Presenter: Manel Sabate, Robert-Jan van Geuns, Sunil V. Rao

October 30, 2016

Presentation TCT 2016

Great Debate 2: Implications from NORSTENT: BMS will Continue to Play an Important Role!

Presenter: Manel Sabate, Robert-Jan van Geuns, Eric R. Bates

October 30, 2016

News Conference News TCT 2016

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

Yael L. Maxwell

October 30, 2016

Presentation TCT 2015

LEADERS FREE: A Prospective, Double-blind Randomized Trial of a Polymer-Free Biolimus-Eluting Stent vs BMS in Patients With Coronary Artery Disease at High Risk for Bleeding

Presenter: Philip M. Urban

October 14, 2015

News Conference News TCT 2015

MASTER: Positive Results Seen for Bioresorbable-Polymer DES in STEMI

October 14, 2015

News Conference News TCT 2015

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Yael L. Maxwell

October 14, 2015

News Conference News TCT 2015

Debaters Question Need for Further Stent Innovation

Todd Neale

October 13, 2015

Presentation TCT 2015

DCBs Plus Adjunctive BMS Use: Current Use, Rationale, and Pitfalls

Presenter: Krishna J. Rocha-Singh, Andrej Schmidt

October 12, 2015

News Conference News TCT 2015

Very Late Stent Thrombosis Remains an Important Clinical Target

October 12, 2015

News Conference News TCT 2015

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

October 12, 2015

Presentation TCT 2015

In Which Patients (if Any) Should BMS Be Used in 2015? Evidence and Common Sense

Presenter: John A. Bittl, E. Magnus Ohman, Marco Valgimigli

October 11, 2015

Advertisement

Debate: How should SFA Disease be Treated? In most cases DCB (± BMS)

Emerging Thromboresistant BMS 1: Cobra PzF Stents

Should BMS Stay On the Shelf? Clinical and Global Perspectives on the Role Of BMS in 2017

The Alphabet of Peripheral Vascular Devices: BMS, DES, PTFE, BVS, and Future Scaffolds

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Imaging Study Shows Rate of Strut Coverage and Low Rates of Neouatherosclerosis with Thin Strut Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

The Alphabet Soup of SFA Scaffolds and Their Outcomes: BMS, VMI, DES, PTFE

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

New Insights Into the Mechanisms and Patterns of in-stent Restenosis in BMS and DES Evaluated By IVUS and OCT (With Case Examples)

Great Debate 2: Implications from NORSTENT: BMS Are Yesterday's History!

Great Debate 2: Implications from NORSTENT: BMS will Continue to Play an Important Role!

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

LEADERS FREE: A Prospective, Double-blind Randomized Trial of a Polymer-Free Biolimus-Eluting Stent vs BMS in Patients With Coronary Artery Disease at High Risk for Bleeding

MASTER: Positive Results Seen for Bioresorbable-Polymer DES in STEMI

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Debaters Question Need for Further Stent Innovation

DCBs Plus Adjunctive BMS Use: Current Use, Rationale, and Pitfalls

Very Late Stent Thrombosis Remains an Important Clinical Target

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

In Which Patients (if Any) Should BMS Be Used in 2015? Evidence and Common Sense

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content